Article Text

Download PDFPDF
  1. Sarah Healy1,
  2. Taha Nasser1,
  3. Mark Willis1,2,
  4. Ilaria Muller1,2,
  5. Katharine Harding1,2,
  6. Trevor Pickersgill1,
  7. Mark Wardle1,
  8. Colin Dayan1,2,
  9. Neil Robertson1,2
  1. 1 University Hospital of Wales
  2. 2 Cardiff University


Introduction Alemtuzumab is effective in active relapsing MS, although autoimmune disease (AID) is a recognised adverse event. We present long-term outcomes of the most common AID (thyroid), in order to inform pre-treatment counselling and subsequent disease management.

Methods 87 patients treated with alemtuzumab were followed within an active surveillance program and detailed data collected prospectively. Standard clinical indices, thyroid diagnosis, thyroid function tests, thyroid autoantibodies and treatment were recorded.

Results Mean follow-up was 7.4 years. 31 (36%,24F:7M) developed thyroid AID. Mean interval from first treatment was 3.0 years (range 0.8–8.7); peak incidence in years 2–3. 12 (38.7%) patients developed hyperthyroidism, 8 (25.8%) subclinical hyperthyroidism, 8 (25.8%) hypothyroidism and 3 (9.7%) subclinical hypothyroidism. In 23 (74%) patients TPO antibodies were present during the disease course. Of 11 patients with hypothyroidism, 6 (55%) were TRAb positive. All patients received appropriate initial treatment for thyroid dysfunction. Three (9.7%) required propylthiouracil and 5 (16%) radioiodine. Two patients (6%) underwent thyroidectomy. No patients developed thyroid carcinoma.

Discussion Thyroid AID following alemtuzumab is a unique model of human autoimmunity and exhibits a variable presentation. When identified early and managed with specialist support it responds to standard treatments. AID can occur outside the recommended 4-year monitoring window and neurologists should remain vigilant for symptoms and have protocols for management.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.